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Table. 1-year outcomes according to bifurcation treatment
Bifurcation
(n=1,317)
No bifurcation
(n=7,266) p value
MACE (Cardiac death, MI or TLR) 8.79% 6.48% 0.002
Cardiac death 0.79% 1.10% 0.31
MI (any) 4.02% 3.05% 0.067
Peri-procedural MI 2.28% 1.27% 0.004
TVR (any) 8.58% 6.41% 0.004
Deﬁnite/probable ST 0.70% 0.86% 0.56
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Background: ADAPT-DES was a prospective, multicenter, real-world registry of
8,583 consecutive pts at 11 international centers undergoing percutaneous coronary
intervention (PCI) with DES designed to determine the frequency, timing, and
correlates of early and late stent thrombosis (ST). Treatment of bifurcation lesions has
been shown to be associated with an increased risk of ST and worse clinical outcome.
We therefore analyzed the impact of bifurcation PCI on outcomes at 1 year.
Methods: Univariable and a fully adjusted multivariable analysis including propensity
score stratiﬁcation were performed to determine the relationship between bifurcation
PCI and subsequent events.
Results: During the index procedure, bifurcation lesions were treated in 1,317
(15.7%) of 8,583 pts. Pts in the bifurcation group were less likely to be female (22.2%
vs. 26.6%, p<0.001), diabetic (28.2% vs. 33.2%, p<0.001), or have ACS (47.2% vs.
52.5%, p<0.001). Post-procedure platelet reactivity was lower among patients
undergoing bifurcation PCI (mean P2Y12 PRU 183 vs. 189, p¼0.017). Pts with
bifurcation PCI had more total stents (2.10 vs. 1.65, p<0.0001) resulting in longer
total stent length (39.2 vs. 31.2 mm, p<0.0001). Bifurcation lesions were more often
in LAD territory (48.9% vs. 37.0%, p<0.0001). Both branches were stented in 19.1%
of all bifurcation lesions, and ﬁnal kissing was done in 46.1%. The 1 year unadjusted
rates of adverse outcomes are shown in the Table. In propensity adjusted models,
bifurcation treatment was not independently associated with 1-year MACE (HR [95%
CI] ¼ 1.13 [0.89, 1.42, p¼0.32), cardiac death (0.75 [0.31, 1.54], p¼0.43), ST (0.64
[0.30, 1.36], p¼0.24), or TVR (1.13 [0.89, 1.43], p¼0.31).
Conclusions: These data, drawn from a large prospective registry of contemporary
DES use, show that bifurcation lesion treatment is frequent, and is not necessarily
associated with a worse prognosis at 1 year.B126 JACC Vol 62/18/Suppl B j October 27–November 1, 2TCT-404
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Background: POLBOS is the randomized, prospective, multicentre study planned to
compare two intervention strategies for bifurcation treatment: provisional T-stenting
(PTS) with any regular drug-eluting stent (DES) and dedicated bifurcation paclitaxel-
eluting stent BiOSS Expert (Balton, Poland).
Methods: Between September 2010 and December 2012 in four centers in Poland
patients with stable CAD or NSTE-ACS were randomized to the group where BiOSS
Expert was implanted or to the group where regular DES was used. An angiographic
control was planned at 12 months in all patients. The primary end-point of the study is
the rate of death, MI, ST and TLR after 12 months. At the time of TCT 2013 complete
clinical 9-month follow-up will be available as well as 90% of angiographic controls
after 12 months.
Results: BiOSS Expert was implanted in 119 patients (49.4%) and regular DES was
implanted in 122 patients (50.6%). The average age of patients did not differ signif-
icantly between groups (BiOSS vs DES: 66.5 vs 66.8 yrs). In BiOSS group there were
signiﬁcantly more patients with NSTE-ACS (9.6% vs 3.5%), diabetes (32.2% vs
16.8%), prior MI and prior CABG. In DES group there were more patients addicted to
smoking (13% vs 22.1%). The dominant vessel was LAD (BiOSS vs DES: 52.1% vs
70.5%) followed by LMS (22.7% vs 13.9%, respectively). In DES group 35.4% of
stents eluted paclitaxel (PES). There were following nominal stent parameters in
BiOSS group: 3.690.36mm x 2.990.36mm x 16.961.44mm and in DES group:
3.270.49mm x 20.66.96 mm. Except for 2 (1.64%) cases in DES group and 1
(0.84%) in BiOSS group all stents were implanted successfully. There were 16%
(BiOSS) and 11.2% (DES) cases with second stent implanted within the side branch.
At six months all patients were uneventful. Up to now control angiography was
performed in 76% of patients in BiOSS group and in 74% in DES group. TLR was,
respectively, 10.99% vs 8.9% (p ¼ 0.5). Nevertheless, within DES group TLR in PES
subgroup was 12.8% and in –olimus subgroup – 5.7%
Conclusions: 9-month follow-up showed that BiOSS Expert provides satisfactory
results which seem to be inferior to those obtained by means of –limus eluting stents,
but comparable with those of PES.
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Background: The provisional T-stenting (PTS) is the recommended strategy for the
coronary bifurcation treatment. However, results obtained with use of regular drug
eluting stents (DES) are not optimal and relatively often associated with a side branch
compromise and restenosis. Dedicated bifurcation stents are claimed to be a solution
for these complications. POLBOS II study is the continuation of POLBOS study,
which paclitaxel-eluting stent BiOSS Expert was assessed in.
Methods: It is a randomized multicenter study planned to compare two strategies for
the bifurcation treatment – PTS with any regular DES or with a dedicated bifurcation
sirolimus-eluting stent BiOSS LIM (Balton, Poland) in patients with CAD or NSTE-
ACS. An angiographic control was planned at 12 months in all patients. The primary
end-point of the study is the rate of death, MI, ST and TLR after 12 months. The aim
is to enroll 120 patients (60 in each group).
Results: The enrollment started in November 2012. To date, 75 patients (64% males)
were randomized (40 inBiOSS group, 35 inDES group). The average agewas 649 yrs.
The dominant vessel was LAD (50%) followed by LMS (33%). 72% of cases were true
bifurcations. All stents were implanted successfully. There were 12.5 and 14.3% of013 j TCT Abstracts/POSTER/Bifurcation and Left Main Interventions
